SAN DIEGO, July 2, 2018 – Diagnomics, Inc., a leading provider for precision medicine solutions based on genomics technology, proudly…
Dr. Min-Jeong Kim
Dr. Min-Jeong Kim is a broadly trained biologist who has vast experience with microarrays and next-generation sequencing (NGS) methodology and analysis using human, plant, animal and microbial sources. He has worked in academic or commercial settings. He received his Ph.D. from Seoul National University in Korea and worked at GreenGene Biotech., where he managed instruments for high-throughput automation, apllied for genome and transcriptome analysis. In 2010, he joined the Dr. Gang lab at the Institute of Biological Chemistry, Washington State University, where he has been working on plant tissue-specific gene expression studies. He continued his scientific work at the Ohio University as the appointed director for the genomics facility before he moved back to Korea to work as R&D director at the EONE-Diagnomics Genome Center (EDGC) . There, he co-developed and validated an innovative non-invasive prenatal test (NIPT) as well as BRCA1/2 clinical testing. He also designed a germline cancer panel for 29 genes and developed a blood collection tube for cell-free DNA extraction. Additionally, he worked on developing a liquid biopsy method to detect somatic DNA variants in the blood of the cancer patients. In 2017, he came back to the US to join Diagnomics, where he has been working on developing a clinical assay pipeline for SNP microarray and NGS-based platforms.